A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer

An Open Label, Phase 1, First-in-human, Study to Evaluate Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of Schlafen12 Complex Inducer (SLFN12 ci) BAY 2666605 in Participants With Metastatic Melanoma and Other Advanced Solid Tumors.

Researchers are looking for a better way to treat people who have advanced cancer.

In this study researchers want to learn more about a new substance called BAY2666605. BAY2666605 triggers the formation of a complex of two proteins called SLFN12 and PDE3A. This complex drive cancer cells into cell death by a mechanism called apoptosis. The complex is only formed in the cancers which contain both proteins.

This study is done in adult patients who have certain types of advanced cancers that cannot be cured by drugs that are currently available. The cancer types include skin cancer that has spread to other parts of the body and cancer that started in the bones or soft tissue, the ovaries, or the brain. Patients with these cancers are only included if the cells of the patient's cancer contain the building plan to produce SLFN12-phosphodiesterase 3A (PDE3A) complex. To confirm this, a specific test is performed with the cancer cells.

The researchers will study how BAY2666605 moves into, through and out of the body. Researchers will try to find the best dose that can be given, how safe BAY2666605 is and how it affects the body. Researchers will also study the action of BAY2666605 against the cancer. Part A will include about 36 participants and up to another 12 participants. Part B will include about 41 participants. All of the participants will take BAY2666605 by mouth as either a liquid or as tablets.

During the study, the participants will take the treatment in 4 week periods called cycles. In each cycle, the participants will in general take BAY2666605 once daily. The participants may also be asked to do overnight fasting before the intake of substance and to have standard high-fat, high-calorie breakfast on some days before taking the dose.

These 4 week cycles will be repeated throughout the trial. The participants can take BAY2666605 until their cancer gets worse, until they have medical problems, or until they leave the trial. Participants will have around 18 visits in each cycle. Some of the visits can also be done via Phone.

During the trial, the study team will take blood and urine samples, do physical examinations and check the participants' heart health using an electrocardiogram (ECG) and an ultrasound of the heart. The study team will also take pictures of the participants' tumors using CT or MRI scans. The study team will ask how the participants are feeling, if participants have any medical problems or if participants are taking any other medicine. About 1 month and 3 months after the last dose, the participants will have another visit and a phone call respectively where participants will be checked for and asked about medical problems. The researchers will then contact the participants every 3 months until the trial ends.

Study Overview

• Status: Terminated
• Conditions: Metastatic Melanoma and Other Solid Tumors
• Intervention / Treatment: Drug: BAY2666605

• Study Type: Interventional
• Enrollment (Actual): 5
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Tennessee
    • Nashville, Tennessee, United States, 37203
      • Sarah Cannon Development Innovations
  • Texas
    • Houston, Texas, United States, 77030
      • University of Texas MD Anderson Cancer Center
    • San Antonio, Texas, United States, 78229-3307
      • South Texas Accelerated Research Therapeutics | START San Antonio

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Pre-screening:

• Signed informed consent for pre-screening
• Male or female participants aged ≥ 18 years
• Participants with histologically confirmed diagnosis of melanoma, glioblastoma/anaplastic astrocytoma, sarcoma or epithelial ovarian cancer/fallopian tube/primary peritoneal cancer
• Availability of archival tumor tissue (5-10 for prescreening, further 20 to be provided at screening)
• ECOG ≤2

Main Screening :

• Positive SLFN12/PDE3A expression in archival tumour
• Minimum life expectancy at least 12 weeks
• Documented radiological disease progression after treatment with all available standard of care therapies for advanced/metastatic disease and at least one measurable lesion
• Adequate bone marrow, liver, and renal function
• Adequate blood clotting
• Left ventricular ejection fraction >50%
• All AEs due to previous therapies to CTCAE Grade ≤1. Grade ≤2 neuropathy, fatigue, alopecia, or anorexia, for which further resolution is not expected, may be eligible.
• Negative pregnancy test and use of highly effective contraception
• Signed informed consent for main screening

Exclusion Criteria:

Pre-screening:

• Any malabsorption conditions
• Known HIV infection, active HBV or HCV infection
• Known hypersensitivity to PDE3 inhibitors, or excipients in the formulation; concomitant treatment with any other PDE3 inhibitors
• Participants with clinically relevant cardiovascular diseases and/or relevant ECG findings
• Participants with history of hemorrhage, bleeding disorders or platelet function abnormalities, aneurysm or aneurysmal vasculopathy; Participants with arterial thromboembolic events (ATEs) or venous thromboembolic events (VTEs), including transient ischemic attacks or pulmonary embolism within 6 months before the start of BAY 2666605 or deep vein thrombosis within 3 months before the start of BAY 2666605; Participant with a history of gastrointestinal (GI) ulcerations or perforation, fistula formation involving any internal organs.

Main screening

• Moderate or severe hepatic impairment
• History of organ allograft transplantation, including allogeneic bone marrow
• Previous of co-existing cancer(s) distinct in primary site or histology from the cancer evaluated in this study (with few exceptions)
• Participants with any history of primary meningeal tumors and/or Any active symptomatic or untreated central nervous system (CNS) metastases and/or a number of prior and concomitant therapies
• Major surgery, significant trauma, serious non-healing wound, wound healing complications, ulcer or bone fracture within 4wks prior to 1st dose

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dose escalation of BAY2666605; Approximately 7 or 8 dose levels are planned.	Drug: BAY2666605; One oral solution strength of BAY2666605 will be used. Two different tablet strengths of BAY2666605 will be available.
Experimental: Dose expansion of BAY2666605; Participants will receive BAY 2666605 at the dose and regimen declared safe in the dose escalation part.	Drug: BAY2666605; One oral solution strength of BAY2666605 will be used. Two different tablet strengths of BAY2666605 will be available.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence and severity of TEAEs including TESAEs	TEAEs: Treatment emergent adverse events; TESAEs:Treatment emergent serious adverse events	Up to 6 months after the last participant's first study intervention or until the end of the study, whichever comes first.
The incidence of DLTs at each dose level in the Dose Escalation part of the study	DLT: Dose limiting toxicity	Up to 28 + 14 days
Maximal plasma exposure (Cmax) of BAY2666605		Cycle 1 Day 1
AUC(0-24) of BAY2666605		Cycle 1, Day 1
RP2D of BAY2666605	RP2D: Recommended phase 2 dose. RP2D will be defined in the expansion part.	Up to 6 months after the last participant's first study intervention or until the end of the study, whichever comes first.
Cmax,md of BAY2666605		Cycle 1, Day 15
AUC(0-24)md of BAY2666605		Cycle 1, Day 15

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ORR	ORR: Objective response rate	Up to 6 months after the last participant's first study intervention or until the end of the study, whichever comes first.
DCR	DCR: Disease control rate	Up to 6 months after the last participant's first study intervention or until the end of the study, whichever comes first.
DOR	DOR: Duration of response	Up to 6 months after the last participant's first study intervention or until the end of the study, whichever comes first.
PFS by investigator assessment	PFS: Progression-free survival	Up to 6 months after the last participant's first study intervention or until the end of the study, whichever comes first.
OS	OS: Overall survival	Up to 6 months after the last participant's first study intervention or until the end of the study, whichever comes first.

Collaborators and Investigators

• Sponsor: Bayer

Publications and helpful links

Helpful Links

• Click here to find further information and, after study completion, the study results according to Bayer's transparency standards.

Study record dates

Study Major Dates

• Study Start (Actual): April 15, 2021
• Primary Completion (Actual): November 9, 2022
• Study Completion (Actual): April 27, 2023

Study Registration Dates

• First Submitted: March 5, 2021
• First Submitted That Met QC Criteria: March 19, 2021
• First Posted (Actual): March 22, 2021

Study Record Updates

• Last Update Posted (Estimated): December 14, 2023
• Last Update Submitted That Met QC Criteria: December 8, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neuroendocrine Tumors; Nevi and Melanomas; Melanoma
• Other Study ID Numbers: 20733 (Registry Identifier: DAIDS-ES Registry Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

IPD Plan Description

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No